Illinois is currently home to 2681 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Chicago, Peoria, Springfield and Urbana. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease
NCT06126224
Recruiting
This is a Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of KarXT in male and female subjects who are aged 55 to 90 years and have mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD. The primary objective of the study is to evaluate the efficacy of KarXT compared with placebo in the treatment of subjects with psychosis associated with AD as measured by the Neuropsychiatric Inventory-Clinician (... Read More
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
06/17/2024
Locations: Clinical Trial Site, Elgin, Illinois
Conditions: Psychosis Associated With Alzheimer's Disease
Register for Updates
FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)
NCT06111586
Recruiting
This is a randomized, parallel group, double-blind Phase 2 study that consists of 2 parts. In Part A the safety of the highest dose-level of frexalimab in adults (age range 18-35 y.o.) will be established. In Part B, a dose-finding study (adolescents and young adults, 12-21 y.o.) evaluating the safety and efficacy of 3 age-adjusted dose-levels of frexalimab in comparison with placebo in participants with newly diagnosed T1D on insulin treatment. The purpose of this study is to determine safety a... Read More
Gender:
All
Ages:
Between 12 years and 35 years
Trial Updated:
06/17/2024
Locations: NorthShore University HealthSystem Site Number : 8400007, Skokie, Illinois
Conditions: Type 1 Diabetes Mellitus
Register for Updates
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
NCT06105632
Recruiting
The purpose of this study is to learn about the safety and how effective the study medicine (PF-07220060) plus fulvestrant is compared to the study doctor's choice of treatment in people with advanced or metastatic breast cancer. Advanced cancer is the one that is unlikely to be cured or taken care of with treatment. Metastatic cancer is the one that has spread to other parts of the body. This study is seeking female and male participants who: are 18 years of age or older; are hormone receptor... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Ascension Illinois - Evanston Infusion Center, Evanston, Illinois
Conditions: Advanced or Metastatic Breast Cancer
Register for Updates
A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)
NCT06101095
Recruiting
This is parallel, Phase 4 study which consists of a 24 week (0.5 years) randomized, double blind, placebo controlled, 2-arm treatment period followed by an open label segment of 104 weeks (2 years) for a total of 128 weeks (2.5 years) to evaluate the effect of dupilumab treatment on esophageal function, and remodeling in adults with eosinophilic esophagitis. Duration of study period (per participant) Screening period: Up to 12 weeks before Week 0 Randomized double-blind period: 24 weeks Open l... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: GI Alliance - Glenview Site Number : 8400012, Glenview, Illinois
Conditions: Eosinophilic Oesophagitis
Register for Updates
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
NCT06098079
Recruiting
A randomized, double-blinded, placebo controlled study intended to capture cardiovascular outcomes during real-world use of naltrexone/bupropion (NB).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: NextStage Clinical Research-Chicago, Glen Ellyn, Illinois
Conditions: Obesity
Register for Updates
A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain
NCT06074562
Recruiting
The main purpose of this study is to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropathic pain (DPNP). The study will lasts approximately 24 weeks, across 3 study periods.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Northwestern University, Chicago, Illinois
Conditions: Diabetic Peripheral Neuropathy
Register for Updates
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
NCT06063967
Recruiting
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the bowels. It can cause many different symptoms including abdominal pain, diarrhea, tiredness, and weight loss. This study will assess how safe and effective risankizumab subcutaneous (SC) induction treatment is in treating moderately to severely active CD in adult participants. Risankizumab is an approved drug for adults with CD. This study comprises... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: GI Alliance - Glenview /ID# 257744, Glenview, Illinois
Conditions: Crohn's Disease
Register for Updates
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738
Recruiting
This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine therapy in combination with a CDK4/6 inhibitor.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Clinical Trial Site, Urbana, Illinois
Conditions: Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
Register for Updates
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
NCT06012435
Recruiting
This clinical trial is studying nonsquamous non-small cell lung cancer (NSCLC). Participants in this study must have cancer that has spread through their body or can't be removed with surgery. Participants in this study must have been treated with no more than a platinum-based chemotherapy and an anti-PD-(L)1 drug. Participants with tumors that have certain treatable genomic alterations must have had at least 1 drug for that genomic alteration, in addition to platinum-based chemotherapy. This c... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Illinois Cancer Care, Niles, Illinois
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis
NCT05969223
Recruiting
Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques. This study will assess how safe and effective risankizumab is in adult participants with moderate to severe genital psoriasis or moderate to severe scalp psoriasis. Adverse events and change in disease signs and symptoms will be monitored. Risankizumab (Skyrizi) is a drug being studied for the treatment of moderate to severe genital psoriasis or moderate to severe sca... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: DeNova Research /ID# 264063, Chicago, Illinois
Conditions: Genital Psoriasis, Scalp Psoriasis
Register for Updates
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
NCT05931367
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or are overweight and have osteoarthritis (OA) of the knee. The study will lasts about 77 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Northwestern University, Chicago, Illinois
Conditions: Obesity, Overweight, Osteo Arthritis Knee
Register for Updates
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
NCT05929066
Recruiting
The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Northwestern University, Chicago, Illinois
Conditions: Obesity, Overweight, Knee Pain Chronic, Knee Osteoarthritis, Obstructive Sleep Apnea
Register for Updates